BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BC Week In Review | Jul 11, 2016
Financial News

Oragenics completes private placement

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla.   Business: Dental, Infectious, Diagnostic   Date completed: 2016-06-30   Type: Private placement   Raised: $4.7 million   Shares: 9 million   Price: $0.52   Shares after offering: 49.1 million...
BC Week In Review | Aug 24, 2015
Clinical News

Intrexon, Oragenics preclinical data

In rodents infected with C. difficile, Oragenics’ lead clinical candidate from its set of MU1140 analogs led to a 100% survival rate vs. 33% for vancomycin and 0% for placebo. The analogs are lantibiotic peptides...
BC Week In Review | Aug 3, 2015
Company News

Intrexon, Oragenics deal

Intrexon granted Oragenics exclusive, worldwide rights to develop and commercialize biotherapeutics based on the ActoBiotics genetically modified Lactococcus lactis platform, including AG013 , to treat oral mucositis (OM) and other diseases of the oral cavity, throat...
BC Week In Review | Nov 10, 2014
Company News

Oragenics management update

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla.   Business: Dental, Infectious, Diagnostic   Resigned: John Bonfiglio as president, CEO and a director; CFO Michael Sullivan becomes interim principal executive officer  ...
BC Week In Review | Apr 28, 2014
Company News

Oragenics management update

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla.   Business: Dental, Infectious, Diagnostic   Hired: Al Fosmoe as SVP of operations/product development  ...
BC Week In Review | Nov 25, 2013
Financial News

Oragenics completes follow-on

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla.   Business: Dental, Infectious, Diagnostic   Date completed: 11/15/13   Type: Follow-on   Raised: $11 million   Shares: 4.4 million   Price: $2.50   Shares after offering: 34.9 million  ...
BC Week In Review | Oct 14, 2013
Company News

Intrexon, Oragenics deal

Oragenics and Intrexon partnered to develop and commercialize genetically modified probiotics to treat diseases of the oral cavity, throat, sinus and esophagus, with an initial focus on Behcet's disease and aphthous stomatitis. Intrexon will be...
BC Week In Review | Aug 19, 2013
Financial News

Oragenics financial update

Oragenics filed a shelf registration covering the sale of up to $30 million of its securities. The company, which closed Friday at $3.09, has 27.5 million shares outstanding. Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla.   Business:...
BC Week In Review | Apr 15, 2013
Financial News

Oragenics financial update

Oragenics began trading on the NYSE MKT under the symbol "OGEN." Previously, the stock traded on the OTC Bulletin Board. *** Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla.   Business: Dental, Infectious, Diagnostic   Date announced: 4/8/13...
Items per page:
1 - 10 of 65
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BC Week In Review | Jul 11, 2016
Financial News

Oragenics completes private placement

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla.   Business: Dental, Infectious, Diagnostic   Date completed: 2016-06-30   Type: Private placement   Raised: $4.7 million   Shares: 9 million   Price: $0.52   Shares after offering: 49.1 million...
BC Week In Review | Aug 24, 2015
Clinical News

Intrexon, Oragenics preclinical data

In rodents infected with C. difficile, Oragenics’ lead clinical candidate from its set of MU1140 analogs led to a 100% survival rate vs. 33% for vancomycin and 0% for placebo. The analogs are lantibiotic peptides...
BC Week In Review | Aug 3, 2015
Company News

Intrexon, Oragenics deal

Intrexon granted Oragenics exclusive, worldwide rights to develop and commercialize biotherapeutics based on the ActoBiotics genetically modified Lactococcus lactis platform, including AG013 , to treat oral mucositis (OM) and other diseases of the oral cavity, throat...
BC Week In Review | Nov 10, 2014
Company News

Oragenics management update

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla.   Business: Dental, Infectious, Diagnostic   Resigned: John Bonfiglio as president, CEO and a director; CFO Michael Sullivan becomes interim principal executive officer  ...
BC Week In Review | Apr 28, 2014
Company News

Oragenics management update

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla.   Business: Dental, Infectious, Diagnostic   Hired: Al Fosmoe as SVP of operations/product development  ...
BC Week In Review | Nov 25, 2013
Financial News

Oragenics completes follow-on

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla.   Business: Dental, Infectious, Diagnostic   Date completed: 11/15/13   Type: Follow-on   Raised: $11 million   Shares: 4.4 million   Price: $2.50   Shares after offering: 34.9 million  ...
BC Week In Review | Oct 14, 2013
Company News

Intrexon, Oragenics deal

Oragenics and Intrexon partnered to develop and commercialize genetically modified probiotics to treat diseases of the oral cavity, throat, sinus and esophagus, with an initial focus on Behcet's disease and aphthous stomatitis. Intrexon will be...
BC Week In Review | Aug 19, 2013
Financial News

Oragenics financial update

Oragenics filed a shelf registration covering the sale of up to $30 million of its securities. The company, which closed Friday at $3.09, has 27.5 million shares outstanding. Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla.   Business:...
BC Week In Review | Apr 15, 2013
Financial News

Oragenics financial update

Oragenics began trading on the NYSE MKT under the symbol "OGEN." Previously, the stock traded on the OTC Bulletin Board. *** Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla.   Business: Dental, Infectious, Diagnostic   Date announced: 4/8/13...
Items per page:
1 - 10 of 65